Long-term Follow-up and Quality of Life of Patients Treated With Anticancer Drugs
Launched by INSTITUT RAFAEL · Mar 14, 2024
Trial Information
Current as of July 24, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is focused on understanding how innovative and expensive anticancer drugs affect the quality of life for patients being treated at the Rafael Institute. The study aims to gather important information about the safety and effectiveness of these treatments in real-life situations, while also measuring how patients feel and cope during their treatment journey. By collecting this data, researchers hope to better understand the needs of cancer patients and improve future care.
To participate in this trial, you need to be an adult aged 18 or older, currently receiving one of the specified anticancer drugs, and able to understand French. Unfortunately, individuals under 18, those under guardianship, or those unable to give consent are not eligible. If you join the study, you can expect to share your experiences and insights about your treatment, which will contribute to a better understanding of how these drugs impact daily life for patients like you.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Age equal to or greater than 18 years (adult)
- • Patients treated with an anticancer drug included in the list of innovative/expensive therapies (protocol appendix)
- • Patients benefiting from non-pharmacological treatment at the Rafael Institute
- • Who understands the French language
- Exclusion Criteria:
- • \< 18 years old
- • Patient deprived of liberty, under guardianship or unable to give consent
About Institut Rafael
Institut Rafael is a leading clinical research organization dedicated to advancing medical knowledge through innovative and rigorous clinical trials. With a strong emphasis on patient safety and ethical standards, Institut Rafael collaborates with healthcare professionals and institutions to develop and evaluate new therapeutic interventions across various medical fields. Committed to fostering scientific excellence, the organization utilizes state-of-the-art methodologies and technologies to ensure high-quality data collection and analysis, ultimately aiming to improve patient outcomes and contribute to the evolution of healthcare practices.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Levallois Perret, Institut Rafael, France
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported